Skip to content

Study · Randomized controlled trial · n = 20 · 2000

6 results

Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.

Wessells H, Levine N, Hadley ME, Dorr R, Hruby V

International journal of impotence research1 Oct 2000Cited by 66 (Europe PMC)

PMID11035391 (opens in a new tab)DOI10.1038/sj.ijir.3900582 (opens in a new tab)PepBankPUB-11035391
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In men with erectile dysfunction, Melanotan II led to penile erection in 17 of 20 men without sexual stimulation.

    In plain wordsIn men with erectile dysfunction, Melanotan II led to an erection in 17 of 20 men without sexual stimulation.

    Peptide
    Melanotan II
    Outcome
    Not applicablePenile erection without sexual stimulation
    Study

    n = 20

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    men with erection
    17 of 20 men
    Melanotan II

    Source sentences

    Summary
    In the absence of sexual stimulation, Melanotan II led to penile erection in 17 of 20 men.
    2 context sentences
    Summary · context
    We review our experience with Melanotan II, a non-selective melanocortin receptor agonist, in human subjects with erectile dysfunction (ED).
    Summary · context
    Melanotan II was administered to 20 men with psychogenic and organic ED using a double-blind placebo-controlled crossover design.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In men with erectile dysfunction, Melanotan II produced a mean of 41 minutes of RigiScan tip rigidity above 80%.

    In plain wordsIn men with erectile dysfunction, Melanotan II produced on average 41 minutes of firm erection measured by RigiScan.

    Peptide
    Melanotan II
    Outcome
    Not applicableDuration of tip rigidity above 80%
    Study

    n = 20

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    mean tip rigidity >80%
    41 min
    Melanotan II

    Source sentences

    Summary
    Subjects experienced a mean of 41 min Rigiscan tip rigidity>80%.
    2 context sentences
    Summary · context
    We review our experience with Melanotan II, a non-selective melanocortin receptor agonist, in human subjects with erectile dysfunction (ED).
    Summary · context
    Melanotan II was administered to 20 men with psychogenic and organic ED using a double-blind placebo-controlled crossover design.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In men with erectile dysfunction, increased sexual desire was reported after 13 of 19 Melanotan II doses versus 4 of 21 placebo doses.

    In plain wordsIn men with erectile dysfunction, more sexual desire was reported after Melanotan II doses (13 of 19) than after placebo doses (4 of 21).

    Peptide
    Melanotan II
    Outcome
    IncreaseSexual desire
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    doses with increased desire
    13 of 19 doses
    Melanotan II
    doses with increased desire
    4 of 21 doses
    placebo
    P value
    < 0.01
    between groups

    Source sentences

    Summary
    Increased sexual desire was reported after 13/19 (68%) doses of Melanotan II vs 4/21 (19%) of placebo (P<0.01).
    2 context sentences
    Summary · context
    We review our experience with Melanotan II, a non-selective melanocortin receptor agonist, in human subjects with erectile dysfunction (ED).
    Summary · context
    Melanotan II was administered to 20 men with psychogenic and organic ED using a double-blind placebo-controlled crossover design.
  4. 04HumanRandomized controlled trialSafety outcome

    In men with erectile dysfunction, nausea was a frequently reported side effect of Melanotan II.

    In plain wordsIn men with erectile dysfunction, nausea was often reported as a side effect of Melanotan II.

    Peptide
    Melanotan II
    Outcome
    Not applicableNausea
    Study

    n = 20

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Nausea and yawning were frequently reported side effects due to Melanotan II; at a dose of 0.025 mg/kg, 12.9% of subjects had severe nausea.
    2 context sentences
    Summary · context
    We review our experience with Melanotan II, a non-selective melanocortin receptor agonist, in human subjects with erectile dysfunction (ED).
    Summary · context
    Melanotan II was administered to 20 men with psychogenic and organic ED using a double-blind placebo-controlled crossover design.
  5. 05HumanRandomized controlled trialSafety outcome

    In men with erectile dysfunction, yawning was a frequently reported side effect of Melanotan II.

    In plain wordsIn men with erectile dysfunction, yawning was often reported as a side effect of Melanotan II.

    Peptide
    Melanotan II
    Outcome
    Not applicableYawning
    Study

    n = 20

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Nausea and yawning were frequently reported side effects due to Melanotan II; at a dose of 0.025 mg/kg, 12.9% of subjects had severe nausea.
    2 context sentences
    Summary · context
    We review our experience with Melanotan II, a non-selective melanocortin receptor agonist, in human subjects with erectile dysfunction (ED).
    Summary · context
    Melanotan II was administered to 20 men with psychogenic and organic ED using a double-blind placebo-controlled crossover design.
  6. 06HumanRandomized controlled trialSafety outcome

    In men with erectile dysfunction, 12.9% of subjects had severe nausea at a Melanotan II dose of 0.025 mg/kg.

    In plain wordsIn men with erectile dysfunction, 12.9% had severe nausea at a Melanotan II dose of 0.025 mg/kg.

    Peptide
    Melanotan II
    Outcome
    Not applicableSevere nausea
    Study

    n = 20

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.025 mg/kgAs given in this study (human).

    Measurements

    subjects with severe nausea
    12.9%
    0.025 mg/kg

    Source sentences

    Summary
    at a dose of 0.025 mg/kg, 12.9% of subjects had severe nausea.
    2 context sentences
    Summary · context
    We review our experience with Melanotan II, a non-selective melanocortin receptor agonist, in human subjects with erectile dysfunction (ED).
    Summary · context
    Melanotan II was administered to 20 men with psychogenic and organic ED using a double-blind placebo-controlled crossover design.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.